Bold plan for crisis-ridden hospital
The NSW government will have power to terminate the operating contract of the embattled Northern Beaches Hospital as if a default had occurred under proposed legislative amendments, following the tragic deaths of two children.
Two-year-old Joe Massa and newborn Harper Atkinson both died at the Sydney hospital in unrelated incidents since September, leading the government to ban any future public-private partnerships (PPPs) for acute care hospitals.
The state government will next week introduce amendments to a bill by Wakehurst MP Michael Regan, which would allow the government, if required, to terminate the contract of operator Healthscope as if a default had occurred.
It comes after receivers were appointed to Healthscope's parent entities – which the NSW government considers a default – with the bill giving Health Minister Ryan Park power to issue a termination notice if an agreement is not reached. Receivers were appointed to Northern Beaches Hospital operator Healthscope's parent entities in May. NewsWire / Max Mason-Hubers Credit: News Corp Australia
Treasurer Daniel Moohkey would also be empowered to ensure that compensation negotiations occur in a 'reasonable time frame' and that an independent person would be appointed to determine compensation if an agreement is not reached.
Mr Moohkey said the decision was not taken lightly.
'We are now in a position where the Liberal's privatisation mess means Healthscope's receivers are negotiating the future of the Northern Beaches Hospital,' he said.
'While an agreed exit from this failed PPP contract remains my preference – I must ensure the government has the right to step in and protect the Northern Beaches community from this dragging on.'
Mr Park said the state government had 'made it clear from the very beginning that we don't support this sort of arrangement. NSW Treasurer Daniel Mookhey said the decision was not taken lightly. NewsWire / Nikki Short Credit: News Corp Australia
'This is a complex contract but the community deserves certainty.
'The other mob may have created this mess, but we are going to be the ones to clean it up.'
Healthscope is the country's second-largest hospital operator, with a network of 37 hospitals across Australia.
Thousands of staff and patients were left in limbo last month after Canada-based Brookfield Asset Management offered to hand control of the company to lenders.
Despite an $100m funding lifeline by Commonwealth Bank and Westpac last month amid the search for a new owner, Healthscope's future remains in doubt.
Earlier that month, Wakehurst MP Michael Regan introduced a private members bill to ensure no compensation would be payable on behalf of the state if the contract for the Northern Beaches Hospital was voluntarily terminated. Health Minister Ryan Park would have power to issue a termination notice if an agreement is not reached. NewsWire / Nikki Short Credit: News Corp Australia
With trilateral talks ongoing between Healthscope, its receivers, and the Northern Beaches Hospital Taskforce, the state government remained hopeful of a productive outcome, but reserved the right to commit to a voluntary termination.
At the time of the receivership, Healthscope CEO Tino La Spina said the hospital network would 'continue to operate as normal' and that the appointment of receivers 'ensures a stable path to a sale, with no impacts on any hospitals, staff or patients'
'There is no interruption to the outstanding care we provide,' she said.
'The receivers and management share the same goal of maintaining our market leading standards of patient care and protecting the business, the hospitals and our amazing
people.'
McGrathNicol Restructuring had been appointed to work with Healthscope management to complete the sale.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
6 hours ago
- West Australian
ASX Runners of the Week: Amplia, archTIS and Vanadium Resources
If you were looking for correlation between the seemingly continuous breakouts of military hostilities between nuclear-armed nations and the market - good luck. The ASX continued at near all-time highs this week, pulling back a fraction by Friday, as conflict between Iran and Israel continued to rise. The oil price surged a further 10 per cent this week as Israel turned its focus from Iran's nuclear facilities to targeting its oil and gas infrastructure. Uranium stocks were the week's main winners. Surprisingly, they were not fuelled directly by global drivers, but rather by investment heavyweight Sprott's physical uranium trust purchase of $200 million worth of uranium oxide, which was announced on Monday. The result for uranium stocks on the index was deafening. Uranium miners Boss Energy, Paladin Energy and Deep Yellow were among the most heavily shorted on the ASX, making up three of the top 10 shorted companies. A sharp increase in uranium caused a two-fold effect of en masse buying and short seller panic to close out positions, with the big three uranium stocks all surging up 20 per cent on the day. In a rare shake-up, no Australian-based resource companies feature on this week's Bulls N' Bears' ASX Runners list. Instead, the chocolates went to a groundbreaking Aussie biotech story, which could be on to the makings of one of the biggest breakthroughs in oncology treatment in years. AMPLIA THERAPEUTICS (ASX: ATX) Up 339% (5.7c – 25c) This week's Bulls N' Bears ASX Runner of the Week is biotech trailblazer Amplia Therapeutics, which sent the market into an absolute tailspin thanks to a jaw-dropping set of results from a clinical trial for incredibly nasty pancreatic cancer. On Monday, the company announced a pathological complete response – no detectable signs of cancer - in a patient enrolled in its ACCENT trial of a drug therapy to limit tumour growth. The trial combined the therapy narmafotinib with two other drugs to treat a patient with metastatic (stage IV) pancreatic cancer. After surgery, the patient's primary and metastatic tumours showed no live cancer cells, a unicorn-rare outcome in this brutal disease, where no detectable cancer signs are less common than a sunny day in Melbourne. The market mumbled and murmured through Wednesday, then stacked 42 per cent onto Amplia's share price. Thursday brought a different tune: a second patient, out of 55 enrolled in the trial, achieved a confirmed complete response, with all tumour lesions vanishing for more than two months. In advanced pancreatic cancer, where one complete response in 431 patients is headline-worthy, two in a trial appears groundbreaking. The market lost its collective marbles and the company's shares rocketed to 25 cents per share – up 339 per cent - on Friday with more than $30 million in shares traded on the week. The move also delivered a handy little profit for Amplia's second largest shareholder Acorn Capital, which picked up a further $350,000 worth of shares on Monday, when it saw value before the broader market. Pancreatic cancer is Australia's eighth most common cancer and has a dismal 12.5 per cent five-year survival rate. With United States Food and Drug Administration registration already in the bag, Amplia's drug looks to be on the charge to transform oncology, especially as healthcare systems globally grapple with rising cancer burdens and demand for precision therapies. ARCHTIS LTD (ASX: AR9) Up 287% (6.2c – 24c) Taking out silver on this week's Runners list is cybersecurity expert archTIS Limited, which saw its share price catapult 390 per cent by Wednesday, before the ASX killjoys slammed it into suspension, ending any hopes the company could take out the coveted Bulls N' Bears podium. The company released a duo of blockbuster defence contracts on Monday and Wednesday, before archTIS' management rubbed shoulders with some of the world's cybersecurity elite. On Monday, the company unveiled a US Defence Department contract for 1000 licences for its NC Protect data security software, worth $38,500 a pop for six months, to lock down sensitive data in Microsoft's DoD365 cloud. After months of brutal testing by the prime global contractor, NC Protect came up trumps as the only integrated solution for robust, scalable attribute-based access control. ArchTIS says its product could address a potential 150,000-user rollout across the warfighter network, if it proves a success for the defence department. Amazingly, $100,000 worth of shares traded on Monday, before going supersonic on Tuesday, to push the company's share price up 100 per cent from last week's close on $600,000 shares traded. ArchTIS dropped a second bomb on Wednesday, announcing a three-year $263,185 deal for 400 users with a United Kingdom-based aerospace and defence titan, which is poised to be a blueprint for more than 100,000 potential users in a global Microsoft 365 rollout. The company's share price hit a peak of 24c for a gain of 287 per cent this week, on $1.4 million in intraday trading, before the compliance overlords at the ASX cried 'disorderly market' and placed the company into suspension, where it remains. It's likely a few day traders were caught flat-footed by the suspension and were no doubt scouring around to come up with the cash to settle on trades they had hoped to flip by market close on Wednesday. In a world where cyberattacks are spiking, archTIS' NC Protect could fulfil a crucial defence need. Its ability to secure sensitive communications in cloud environments, such as the DoD365 and Microsoft 365 platforms, is critical as nations race to shield their military and industrial data from state-sponsored threats. With geopolitical tensions boiling and the US and UK doubling down on cybersecurity to protect their defence industrial bases, archTIS' tech is perfectly timed to cash in on the global push for ironclad digital fortresses, making it a potential darling in the market and of Western military alliances. VANADIUM RESOURCES LTD (ASX: VR8) Up 185% (1.3c – 3.7c) Snagging the final spot on the Runners of the Week podium is the aptly named critical minerals developer Vanadium Resources, which shot out of a cannon on Tuesday, after inking a non-binding memorandum of understanding (MoU) with China Precious Asia (CPA). Vanadium will supply 1.2 million tonnes per annum of vanadium-rich magnetite direct shipping ore to the heavyweight global metals trader from its world-class Steelpoortdrift vanadium project in South Africa. The MoU positions Vanadium to tap into early cash flows at the fully permitted Steelpoortdrift, a behemoth resource with 680 million tonnes of ore at 0.70 per cent vanadium oxide, which is equivalent to 4.74Mt contained vanadium. That rate is enough to keep the company's lights on for more than 180 years. CPA will handle loading and collection of the direct shipping ore, with Vanadium retaining a nimble ±25 per cent supply flexibility each month, kicking off by December this year. Management believes the material positive operating cash flows will fast track its development, with good reason. Steelpoortdrift's vanadium-rich ore also brims with iron-rich magnetite, making it a dual-treat commodity in the Asian steel market. The news sent the company's long-beleaguered share price soaring a cheeky 185 per cent from last Friday's 1.3c close to a 3.7c peak on $230,000 in stock traded. Vanadium is also actively sniffing out profit-share deals and acquisitions to bolster its near-term game plan without derailing the direct shipping ore opportunity. The deal looks beneficial for both parties as vanadium supplies are projected to be in global deficit this year, coupled with China's ambitions to diversify from its dependence on Australian-based iron ore. Steelpoortdrift's high-grade, low-cost direct shipping option has reignited global and now market interest in the company. If Vanadium can lock in a binding agreement with CPA, this plucky minnow could vault into the vanadium big league and potentially self-fund its own mine development. Is your ASX-listed company doing something interesting? Contact:
Perth Now
7 hours ago
- Perth Now
Banks, miners drag ASX lower
Gains in the healthcare sector were offset by falls in the big four banks and major miners, with the local market falling for its fourth consecutive trading day on Friday. The ASX 200 dropped 18.20 points or 0.21 per cent to 8,505.50 on a quiet day of trading. The broader All Ordinaries slipped 17.90 points or 0.20 per cent to 8,723.50. Australia's dollar traded down against the US dollar and is now buying 64.83 US cents. Five of the 11 sectors rose but falls in banks and mining shares dragged the market lower. NewsWire / Jeremy Piper Credit: News Corp Australia On a mixed day for investors, strong gains out of the utilities and healthcare sectors were offset by falls from the big banks and miners. CSL shares jumped 0.63 per cent to $240.21, Pro Medicus gained 1 per cent to $276.81 and ResMed added 1.40 per cent to $39.16 on a strong day for the healthcare sector. Commonwealth Bank fell from a record high close on Thursday, down 0.2 per cent to $182.53. National Australia Bank slipped 0.5 per cent to $38.91, while Westpac came off 1.1 per cent to $33.21 and ANZ dropped to 2.5 per cent to $28.39. It was a mixed day for the big miners, with BHP eking out a small gain up 0.22 per cent to $36.21, while Rio Tinto fell 1.33 per cent to $102.17 and Fortescue dropped 0.54 per cent to $14.69. Overall five of the 11 sectors closed higher despite the market falling. On a reversal of trade in recent days, the price of oil and gold fell after the White House said US President Donald Trump would decide on strikes on Iran 'within the next two weeks' alleviating fears of an immediate escalation in the Middle East crisis. The price of crude oil futures fell 2.9 per cent to $US76.50 a barrel on the news, while gold futures also dropped 1.4 per cent to $US3,362 an ounce. Healthcare shares are on the rise on an overall weak day of trading: NewsWire / Christian Gilles Credit: News Corp Australia AMP head of investment strategy and chief economist Shane Oliver said stocks remained at 'high risk' of a pullback as markets grappled with multiple economic concerns. 'Global and Australian shares have seen a strong rebound from their April lows – but they remain at high risk of a sharp near term pull back as the risk of an oil supply disruption flowing from the war with Iran is high and Trump's tariff threat is far from resolved,' he said. 'On the tariff front it is notable that the 9th July tariff deadline is rapidly approaching and no deals have been struck beyond that with the UK, with indications that some countries may end up with tariffs well above 10 per cent.' In company news, Pointsbet Holdings announced a temporary pause in trading. It comes as rival sports wagering company Betr announced a renewed takeover bid in what it is calling a superior proposal for Pointsbet compared to Japanese gaming giant Mixi. Web Travel shares are in the red down 0.44 per cent to $4.50 after announcing former Virgin Australia chief executive Paul Scurrah and JB Hi Fi director Melanie Wilson would be joining the board as independent non-executive directors.
News.com.au
17 hours ago
- News.com.au
NSW government seeking power to terminate Northern Beaches Hospital contract
The NSW government will have power to terminate the operating contract of the embattled Northern Beaches Hospital as if a default had occurred under proposed legislative amendments, following the tragic deaths of two children. Two-year-old Joe Massa and newborn Harper Atkinson both died at the Sydney hospital in unrelated incidents since September, leading the government to ban any future public-private partnerships (PPPs) for acute care hospitals. The state government will next week introduce amendments to a bill by Wakehurst MP Michael Regan, which would allow the government, if required, to terminate the contract of operator Healthscope as if a default had occurred. It comes after receivers were appointed to Healthscope's parent entities – which the NSW government considers a default – with the bill giving Health Minister Ryan Park power to issue a termination notice if an agreement is not reached. Treasurer Daniel Moohkey would also be empowered to ensure that compensation negotiations occur in a 'reasonable time frame' and that an independent person would be appointed to determine compensation if an agreement is not reached. Mr Moohkey said the decision was not taken lightly. 'We are now in a position where the Liberal's privatisation mess means Healthscope's receivers are negotiating the future of the Northern Beaches Hospital,' he said. 'While an agreed exit from this failed PPP contract remains my preference – I must ensure the government has the right to step in and protect the Northern Beaches community from this dragging on.' Mr Park said the state government had 'made it clear from the very beginning that we don't support this sort of arrangement. 'This is a complex contract but the community deserves certainty. 'The other mob may have created this mess, but we are going to be the ones to clean it up.' Healthscope is the country's second-largest hospital operator, with a network of 37 hospitals across Australia. Thousands of staff and patients were left in limbo last month after Canada-based Brookfield Asset Management offered to hand control of the company to lenders. Despite an $100m funding lifeline by Commonwealth Bank and Westpac last month amid the search for a new owner, Healthscope's future remains in doubt. Earlier that month, Wakehurst MP Michael Regan introduced a private members bill to ensure no compensation would be payable on behalf of the state if the contract for the Northern Beaches Hospital was voluntarily terminated. With trilateral talks ongoing between Healthscope, its receivers, and the Northern Beaches Hospital Taskforce, the state government remained hopeful of a productive outcome, but reserved the right to commit to a voluntary termination. At the time of the receivership, Healthscope CEO Tino La Spina said the hospital network would 'continue to operate as normal' and that the appointment of receivers 'ensures a stable path to a sale, with no impacts on any hospitals, staff or patients' 'There is no interruption to the outstanding care we provide,' she said. 'The receivers and management share the same goal of maintaining our market leading standards of patient care and protecting the business, the hospitals and our amazing people.'
